Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report

Sara Al-Rasbi; Juhaina Salim Al-Maqbali; Rajaa Al-Farsi; Moza Ali Al Shukaili; Maryam H. Al-Riyami; Zubaida Al Falahi; Hatem Al Farhan; Abdullah M. Al Alawi

doi:10.12659/AJCR.934399

17 February 2022 : Case report Oman

Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report

Unusual clinical course, Challenging differential diagnosis, Diagnostic / therapeutic accidents, Management of emergency care, Unexpected drug reaction, Educational Purpose (only if useful for a systematic review or synthesis)

Sara Al-Rasbi^12ABEF, Juhaina Salim Al-Maqbali^3ABEFG*, Rajaa Al-Farsi^2BE, Moza Ali Al Shukaili^4BE, Maryam H. Al-Riyami^2EF, Zubaida Al Falahi^1EF, Hatem Al Farhan^12AG, Abdullah M. Al Alawi^12AEFG

DOI: 10.12659/AJCR.934399

Am J Case Rep 2022; 23:e934399

Authors information Article notes Copyright and License information

Background Case Report Discussion Conclusions References:

Related articles Order reprints Share article Share by email

View HTML version

Table 3. Results summary of the hospitalization autoimmune tests.

Test	Result
Anti-nuclear antibody (ANA)	Negatives
Anti-Glomerular Basement Membrane Disease (Goodpasture’s Syndrome)	Negative
Autoimmune antiphospholipid syndrome	Negative
Anti-neutrophils cytoplasmic antibody	Negative

Back to the Article

Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report

Your Privacy